The IL3 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of the interleukin 3 (IL3) gene. This product, derived from the widely used HeLa cell line, provides a genetically disrupted IL3 locus across a heterogeneous pool of edited cells, enabling robust functional analyses without clonal selection. The polyclonal format preserves population-level diversity and facilitates direct comparisons with wild-type controls in experiments where pooled knockout phenotypes are informative. The targeted disruption of IL3 creates a powerful tool for dissecting the biological roles of this cytokine in human cellular models.
HeLa cells are an established immortalized cell line originating from a cervical adenocarcinoma and are known to harbor integrated human papillomavirus type 18 (HPV-18) sequences. As epithelial cells, they constitute a foundational model in cancer biology, virology, and signal transduction research. While HeLa cells are not of hematopoietic origin??the primary context for IL3 function??they express many components of cytokine signaling pathways, making them a valuable platform for investigating ectopic or cancer-associated IL3 signaling. The HPV-18 positive status also offers opportunities to study interactions between viral oncoproteins and cytokine networks.
IL3 encodes a pleiotropic cytokine that plays a critical role in the proliferation, differentiation, and survival of hematopoietic progenitor cells. Mechanistically, IL3 binds to a heterodimeric receptor composed of IL3RA (CD123) and CSF2RB (CD131), leading to the activation of Janus kinase 2 (JAK2) and subsequent phosphorylation of signal transducer and activator of transcription 5 (STAT5). This interaction also engages phosphoinositide 3-kinase (PI3K)/AKT and RAS/MEK/ERK cascades, promoting the expression of downstream targets such as Bcl-xL, Cyclin D1, and c-Myc, while suppressing the cyclin-dependent kinase inhibitor p27KIP1. Upstream, IL3 production can be induced by T-cell receptor signaling, CD28 co-stimulation, and pro-inflammatory cytokines including IL-1 and TNF-alpha, with transcription factors NF-??B and AP-1 playing central regulatory roles.
Although IL3 signaling is predominantly studied in the hematopoietic system, the IL3 Knockout HeLa Polyclonal Cells offer a unique epithelial context for exploring non-canonical or aberrant IL3 pathway activation. HeLa cells provide a clean background devoid of endogenous IL3 expression, making them ideal for reconstitution experiments, ectopic expression studies, and off-target drug assessments. This model is particularly relevant given emerging evidence that cytokine receptor components may contribute to solid tumor biology and that IL3 pathway inhibitors are being explored beyond hematological malignancies. The knockout also serves as a negative control for antibody specificity validation and for discriminating IL3-dependent from IL3-independent signaling events.
A broad range of experimental techniques is compatible with this knockout cell product. Researchers can employ RT-qPCR to assess IL3 mRNA levels and confirm gene disruption, ELISA to measure secreted cytokine levels, Western blotting to detect changes in downstream phospho-proteins such as pSTAT5 or pAKT, and immunofluorescence to examine protein localization. Functional assays, including proliferation and apoptosis analyses, allow direct measurement of IL3-dependent cellular responses. CRISPR editing efficiency can be verified through T7 endonuclease I (T7E1) assay and Sanger sequencing. This tool supports drug screening for IL3 pathway inhibitors, mechanistic studies of JAK/STAT, PI3K/AKT, and MAPK/ERK crosstalk, and antibody validation against IL3 signaling components. For additional technical details, protocol recommendations, or batch-specific validation data, please contact Ascent Research.
